bioMérieux Shares Drop Nearly 20% in Three Months, Approaching a Key Support Level
The in vitro diagnostics specialist's stock fell close to 2% this Tuesday, amidst a generally declining Parisian market. This new session of decline adds to a quarterly report already marked by a nearly 20% drop over three months, as the publication of the first quarter revenue approaches.
bioMérieux's stock price stood at 91.85 euros at the end of the day, down 1.92% from last Thursday's close of 93.65 euros. The stock is trading well below its 50-day moving average of 95.21 euros, and even more so below its 200-day moving average of 109.61 euros. This significant gap from the 200-day moving average — over 16% — illustrates the extent of the downturn experienced over the past year, with an annual performance showing a decline of 19.92%. In terms of Bollinger Bands, the stock is positioned in the lower part of the band, about 40% between the lower bound (88.42 euros) and the upper bound (96.91 euros). The technical support identified at 89.10 euros is the next threshold to watch if the downward movement continues. The RSI, at 50, remains in a neutral zone, indicating neither overselling nor particular buying pressure at this stage. The CAC 40 is down 0.48% in the session, at 7,924 points. In the healthcare sector, Sanofi also fell by 2.22%, while UCB limited its decline to 0.23%, indicating a more pronounced selling pressure on French stocks in the segment.
Financial Calendar and Market Sensitivity
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
bioMérieux's financial calendar schedules the publication of the first quarter 2026 revenue on April 23. This deadline comes as the stock has lost nearly 20% over three months, a decline that calls for concrete details on the commercial dynamics of the Lyon-based group. The sequence will continue with the semi-annual results expected on July 28. With a beta of 0.07, the stock remains minimally correlated with general market fluctuations. This low sensitivity coefficient suggests that recent movements are more likely due to factors specific to the group or its industry rather than the macroeconomic environment. The one-month volatility, measured at 5.90, remains contained despite the downward trend. The price is now just over 3% above the support at 89.10 euros, leaving little margin before a potential test of this key level.
SectorSanté · Vaccins et laboratoires de recherche›Équipements Médicaux
Context
Period
Period: 9M 2025
Guidance from the release
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.